Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acasti Pharma (NQ: ACST )

2.440 -0.060 (-2.40%)
Streaming Delayed Price Updated: 2:37 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,368
Open 2.420
Bid (Size) 2.430 (1)
Ask (Size) 2.450 (30)
Prev. Close 2.500
Today's Range 2.410 - 2.540
52wk Range 1.720 - 3.590
Shares Outstanding 44,612,831
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025
ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace
ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024
ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace

Performance

YTD
-11.59%
-11.59%
1 Month
-19.74%
-19.74%
3 Month
-11.59%
-11.59%
6 Month
-20.26%
-20.26%
1 Year
+13.49%
+13.49%

More News

Read More
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Via InvestorPlace
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recap: Acasti Pharma Q4 Earnings
Via Benzinga
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Acasti Pharma (ACST) Stock Is Exploding Higher
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Acasti Pharma's Earnings Outlook
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Acasti Pharma Reports Third Quarter 2023 Operational Results
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
From Acasti Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For February 14, 2023
Via Benzinga
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
Via Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
From Acasti Pharma, Inc.
Via GlobeNewswire
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
From Acasti Pharma, Inc.
Via GlobeNewswire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
From Acasti Pharma, Inc.
Via GlobeNewswire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
From Acasti Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.